Skip to main content
SpringerLink
Log in

Maligne Hyperthermie (MH)

  • Chapter
Die Anästhesiologie

Zusammenfassung

Die maligne Hyperthermie ist eine metabolische Myopathie, die durch volatile Inhalationsanästhetika und depolarisierende Muskelrelaxanzien ausgelöst wird. Durch unkontrollierte intramuskuläre Kalziumfreisetzung kann sich innerhalb von Minuten bis Stunden eine lebensbedrohliche Stoffwechselentgleisung entwickeln (sog. MH-Krise). Anlageträger für eine maligne Hyperthermie sind im alltäglichen Leben nicht erkennbar. Frühzeitige Diagnose und Therapie einer MH-Krise entscheiden über das Schicksal des Patienten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 209.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Anetseder M, Hager M, Müller CR, Roewer N (2002) Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 359: 1579–1580

    Article  PubMed  Google Scholar 

  2. Anetseder M, Ritter L, Horbaschek H, Hartung E, Roewer N (2000) The impact of 4-chloro-m-cresol in heparin formulas on malignant hyperthermia: in vitro and in vivo. Acta Anaesthesiol Scand 44: 338–342

    Article  PubMed  CAS  Google Scholar 

  3. Baur CP, Bellon L, Felleiter P et al. (2000) A multicenter study of 4-chlorom- cresol for diagnosing malignant hyperthermia susceptibility. Anesth Analg 90: 200–205

    Article  PubMed  CAS  Google Scholar 

  4. Baur CP, Klingler W, Jurkat-Rott K et al. (2000) Xenon does not induce contracture in human malignant hyperthermia muscle. Br J Anaesth 85: 712–716,

    Article  PubMed  CAS  Google Scholar 

  5. Baur CP, Schlecht R, Jurkat-Rott K, Georgieff M, Lehmann-Horn F (2002) Anesthesia in neuromuscular disorders. Part 1: Introduction. Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie 37: 77–83

    Article  CAS  Google Scholar 

  6. Brandt A, Schleithoff L, Jurkat-Rott K et al. (1999) Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 8: 2055–2062

    Article  PubMed  CAS  Google Scholar 

  7. Breucking E, Reimnitz P, Schara U, Mortier W (2000) [Anesthetic complications. The incidence of severe anesthetic complications in patients and families with progressive muscular dystrophy of the Duchenne and Becker types]. Anaesthesist 49: 187–195

    Article  PubMed  CAS  Google Scholar 

  8. Burkman JM, Posner KL, Domino KB (2007) Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 106: 901–906

    Article  PubMed  Google Scholar 

  9. Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet 2: 45–50

    Article  Google Scholar 

  10. Deufel T, Sudbrak R, Feist Y et al. (1995) Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19q12–13.2, comprising the C1840T transition in the RYR1 gene. Am J Hum Genet 56: 1334–1342

    PubMed  CAS  Google Scholar 

  11. DGAI (2008) Beschluss des Engeren Präsidiums der DGAI vom 11.04.2008. Empfehlung zur Therapie der malignen Hyperthermie. Anästh Intensivmed 49: 483–488

    Google Scholar 

  12. Duke AM, Hopkins PM, Halsall PJ, Steele DS (2006) Mg2+ dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia. Br J Anaesth 97: 320–308

    Article  PubMed  CAS  Google Scholar 

  13. Girard T, Cavagna D, Padovan E et al. (2001) B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators. J Biol Chem 276: 48077–48082

    PubMed  CAS  Google Scholar 

  14. Glahn KPE, Ellis FR, Halsall PJ et al. (2010) Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. B J Anaesth 105: 417–420

    Article  CAS  Google Scholar 

  15. Harrison GG, Isaacs H (1992) Malignant hyperthermia. An historical vignette. Anaesthesia 47: 54–56

    Article  PubMed  CAS  Google Scholar 

  16. Hartung E, Anetseder M, Olthoff D et al. (1998) [Regional distribution of predisposition to maligant hyperthermia in Germany: tate in 1997]. Anasthesiol Intensivmed Notfallmed Schmerzther 33: 238–243

    Article  PubMed  CAS  Google Scholar 

  17. Hartung E, Anetseder M (2000) The Standard In-Vitro Contracture Test. In: Schulte am Esch JS, Scholz J, Wappler F (eds) Malignant Hyperthermia. Pabst Science, Lengerich, pp 251–261

    Google Scholar 

  18. Hopkins PM, Hartung E, Wappler F (1998) Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. The European Malignant Hyperthermia Group. Br J Anaesth 80: 389–394

    Article  PubMed  CAS  Google Scholar 

  19. Jantzen JP, Eberle B, Gaida BJ et al. (1992) Zur Wirkung von Muskelrelaxanzien auf den Massetertonus : Eine experimentelle Studie am MHdisponerten Schweinemodell Anaesthesist 41: 248–253

    CAS  Google Scholar 

  20. Kim TW, Nemergut ME (2011) Preparation of Modern Anesthesia Workstations for Malignant Hyperthermia-susceptible Patients: Anesthesiology 114: 205–212

    Article  PubMed  Google Scholar 

  21. Klingler W, Lehmann-Horn W, Schulte-Sasse U (2011) Hotline für maligne Hyperthermie. Anaesthesist 60: 172–174

    Article  PubMed  CAS  Google Scholar 

  22. Kunst G, Graf BM, Schreiner R, Martin E, Fink RH (1999) Differential effects of sevoflurane, isoflurane, and halothane on Ca2 +release from the sarcoplasmic reticulum of skeletal muscle. Anesthesiology 91: 179–186

    Article  PubMed  CAS  Google Scholar 

  23. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB (2010) Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 110: 498–507

    Article  PubMed  Google Scholar 

  24. Larach MG for the North American Malignant Hyperthermia Group (1989) Standardization of the caffeine halothane muscle contracture test. Anesth Analg 69: 511–515

    Article  PubMed  CAS  Google Scholar 

  25. Leong P, MacLennan DH (1998) A 37-amino acid sequence in the skeletal muscle ryanodine receptor interacts with the cytoplasmic loop between domains II and III in the skeletal muscle dihydropyridine receptor. J Biol Chem 273: 7791–7794

    Article  PubMed  CAS  Google Scholar 

  26. McCarthy TV, Healy JM, Heffron JJ et al. (1990) Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12–13.2. Nature 343: 562–564

    Article  PubMed  CAS  Google Scholar 

  27. Monnier N, Krivosic-Horber R, Payen JF et al. (2002) Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. Anesthesiology 97: 1067–1074

    Article  PubMed  CAS  Google Scholar 

  28. Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60: 1316–1325

    Article  PubMed  CAS  Google Scholar 

  29. Ording H, Brancadoro V, Cozzolino S et al. (1997) In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 41: 955–966

    Article  PubMed  CAS  Google Scholar 

  30. Paul-Pletzer K, Yamamoto T, Bhat MB et al. (2002) Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem, 277: 34918–34923

    Article  CAS  Google Scholar 

  31. Reber A, Schumacher P, Urwyler A (1993) Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Implications for malignant hyperthermia treatment. Anaesthesia 48: 862–865

    Article  PubMed  CAS  Google Scholar 

  32. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 27: 977–989

    Article  PubMed  CAS  Google Scholar 

  33. Roewer N, Anetseder M (2000) Cardiovascular Alterations. In: Schulte am Esch JS, Scholz J, Wappler F (eds) Malignant Hyperthermia. Pabst Science, Lengerich, pp 134–141

    Google Scholar 

  34. Rosenberg H, Fletcher J, Seitman D (1992) Pharmacogenetics. In: PG Barash, BF Cullen, RK Stoelting (eds) Clinical Anesthesia. Lippincott-Raven, Philadelphia

    Google Scholar 

  35. Rosenberg H, Reed S (1983) In vitro contracture tests for susceptibility to malignant hyperthermia. Anesth Analg 62: 415–420

    Article  PubMed  CAS  Google Scholar 

  36. Saltzman LS, Kates RA, Corke BC, Norfleet EA, Heath KR (1984) Hyperkalemia and cardiovascular collapse after verapamil and dantrolene administration in swine. Anesth Analg 63: 473–478

    Article  PubMed  CAS  Google Scholar 

  37. Schuster F, Scholl H, Hager M etal. (2006) The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg 102: 468–472

    Article  PubMed  CAS  Google Scholar 

  38. Shime J, Gare D, Andrews J, Britt B (1988) Dantrolene in pregnancy: lack of adverse effects on the fetus and newborn infant. Am J Obstet Gynecol 159: 831–834

    PubMed  CAS  Google Scholar 

  39. Tanabe T, Beam KG, Adams BA, Niidome T, Numa S (1990) Regions of the skeletal muscle dihydropyridine receptor critical for excitation-contraction coupling. Nature 346: 567–569

    Article  PubMed  CAS  Google Scholar 

  40. Tong J, Oyamada H, Demaurex N et al. (1997) Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 272: 26332–26339

    Article  PubMed  CAS  Google Scholar 

  41. Urwyler A, Deufel Th, McCarthy T, West S for the European Malignant Hyperthermia Group (2001) Guidelines for the detection of malignant hyperthermia susceptibility. Br J Anaesth 86: 283–287

    Article  PubMed  CAS  Google Scholar 

  42. Van Der Spek AF, Reynolds PI, Fang WB et al. (1990) Changes in resistance to mouth opening induced by depolarizing and non-depolarizing neuromuscular relaxants. Br J Anaesth 64: 21–27

    Article  PubMed  Google Scholar 

  43. Wappler F, Fiege M, Schulte Am EJ (2001) Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth 87: 794–798

    Article  PubMed  CAS  Google Scholar 

  44. www.emhg.org

  45. Zhou J, Allen PD, Pessah IN, Naguib M (2010) Neuromuscular Disorders and Malignant Hyperthermia. In: Miller RD (ed) Miller’s Anesthesia. Churchill Livingstone Elsevier, Philadelphia, pp 1181–1195

    Google Scholar 

  46. Zorzato F, Fujii J, Otsu K et al. (1990) Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 265: 2244–2256

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Anästhesie u. operative Intensivmedizin, Krankenhaus Landshut-Achdorf, Achdorfer Weg 3, 84034, Landshut

    PD Dr. Martin Anetseder

  2. Klinik u. Poliklinik für Anästhesiologie Zentrum Operative Medizin, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg

    Prof. Dr. Norbert Roewer

Authors
  1. PD Dr. Martin Anetseder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Norbert Roewer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für operative Intensivmedizin und Intermediate Care, Universitätsklinikum Aachen, Medizinische Fakultät der RWTH Aachen, Pauwelsstr. 30, 52074, Aachen

    Rolf Rossaint

  2. Klinik für Anästhesiologie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz

    Christian Werner

  3. Klinik für Anästhesiologie, Klinikum der Ludwig-Maximilians-Universität München, Standorte Großhadern und Innenstadt Marchioninistr. 15, 81377, München

    Bernhard Zwißler

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Anetseder, M., Roewer, N. (2012). Maligne Hyperthermie (MH). In: Rossaint, R., Werner, C., Zwißler, B. (eds) Die Anästhesiologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-21125-6_67

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-21125-6_67

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-21124-9

  • Online ISBN: 978-3-642-21125-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation